History

Anastrozole (Arimidex, originator AstraZeneca) was approved by the FDA on December 27, 1995, initially for advanced breast cancer in postmenopausal women progressing after tamoxifen (second-line). Its indications were later expanded to first-line treatment of HR+ or HR-unknown locally advanced/metastatic breast cancer in postmenopausal women, and to adjuvant treatment of postmenopausal women with HR+ early breast cancer (verified against the DailyMed label). The label restricts use to postmenopausal women and warns the drug may cause fetal harm. It is now widely generic, and has investigational off-label use in some pediatric growth/precocious-puberty settings.

Anastrozole, sold as Arimidex, is a non-steroidal aromatase inhibitor: a prescription breast-cancer drug that lowers the body’s estrogen by blocking the enzyme that makes it. It is important to be precise about what anastrozole is and is not. It is not an anabolic-androgenic steroid, not a SERM (selective estrogen receptor modulator like tamoxifen), and not a peptide. It has robust, large-trial evidence in postmenopausal women with breast cancer — and a completely separate, off-label history of use by men who take it alongside anabolic steroids or testosterone to suppress estrogen. This page is educational and harm-reduction oriented and contains no doses, cycles, stacks, or post-cycle protocols.

What it is

Anastrozole is a selective, non-steroidal (Type II), reversible/competitive aromatase inhibitor (AI). Aromatase (CYP19A1) catalyzes the final, rate-limiting step that converts androgens (androstenedione, testosterone) into estrogens (estrone, estradiol) in peripheral tissues such as fat, muscle, and liver. Blocking that enzyme lowers circulating estrogen.

In postmenopausal women, peripheral aromatization is the main source of estrogen, so anastrozole produces large estradiol suppression (roughly 80–90%). It does not meaningfully suppress adrenal corticosteroid or aldosterone synthesis at therapeutic doses.

A key pharmacologic point for the non-medical context: in premenopausal people and men, the hypothalamic-pituitary-gonadal (HPG) axis responds to falling estrogen by increasing gonadotropins, which blunts the estrogen suppression and raises testosterone. That feedback is exactly why men misuse it (see below) — and also why anastrozole is not effective or appropriate as monotherapy in premenopausal women.

The claims

Medical use is well defined: adjuvant and metastatic HR+ breast cancer in postmenopausal women, plus risk-reducing (preventive) use in high-risk postmenopausal women. There is also investigational off-label endocrine use in certain pediatric short-stature/precocious-puberty protocols (e.g., the GAIL study of anastrozole plus leuprorelin in early-maturing girls) — not an approved indication.

Athletes and bodybuilders use anastrozole off-label, outside any medical setting, for a different purpose: taken alongside aromatizing anabolic-androgenic steroids (AAS) or testosterone (TRT), it is used to suppress estrogen and reduce gynecomastia, estrogenic water retention, and other high-estrogen side effects, and in men to raise endogenous testosterone by relieving estrogen-mediated negative feedback on the HPG axis. USADA explicitly notes that AIs are misused to “artificially keep androgen levels high” and to minimize side effects such as breast growth in males. This is unapproved use.

What the evidence actually shows

The human evidence for anastrozole’s approved uses is genuinely strong — large, randomized oncology trials. The evidence for performance/physique use in healthy men is essentially absent.

ATAC trial (adjuvant, ~9,366 postmenopausal women): anastrozole versus tamoxifen versus the combination. At 68-month follow-up, anastrozole improved disease-free survival and time-to-recurrence, reduced contralateral breast cancers, and caused fewer endometrial and thromboembolic events — but more arthralgia and more fractures than tamoxifen (HR 0.87, 95% CI 0.78–0.97 for disease-free survival at the 5-year readout). The 10-year analysis confirmed a durable recurrence benefit with no overall-survival difference. ATAC established anastrozole as a preferred initial adjuvant endocrine option in this population.
IBIS-II prevention trial (3,864 high-risk postmenopausal women, anastrozole vs placebo): about a 50% reduction in breast cancer incidence over the treatment period (first results HR ~0.47; long-term ~49% reduction, 85 vs 165 cases at a median of roughly 131 months). Long-term follow-up showed continued risk reduction with no excess fractures or cardiovascular disease — supporting a genuine chemopreventive effect.
Lipids: the evidence is mixed but generally modest for anastrozole. Meta-analyses show small, variable lipid changes; the data suggest letrozole and exemestane worsen lipids more than anastrozole, while anastrozole has little adverse (or neutral/slightly favorable) lipid effect. It is not as clearly protective as tamoxifen.
Bone: AI therapy consistently shows decreased bone mineral density and increased fracture risk versus tamoxifen or placebo — the best-documented harm.
Men / performance use: controlled-physiology work (Finkelstein et al., NEJM 2013) shows that estrogen suppression in men increases body fat and reduces libido/sexual function, and that AI-driven estrogen suppression contributes to bone loss even when testosterone is maintained. In other words, estrogen is not merely a “side-effect hormone” in men. There is no robust evidence that anastrozole safely or durably enhances athletic performance or body composition in healthy men, and its non-medical use is unstudied for safety in that context.

Legal and regulatory status

US — prescription drug, not a controlled substance. Anastrozole is legal only with a valid prescription. It is not scheduled under the Controlled Substances Act. Selling or distributing it without a prescription, or marketing it inside “dietary supplements,” is unlawful — the FDA and USADA note that AI-type compounds such as arimistane do not meet the definition of a dietary ingredient and cannot legally be in supplements. One label nuance worth getting right: the DailyMed label places “may cause fetal harm” under Warnings / Use in Pregnancy (advising effective contraception during and for at least 3 weeks after therapy), not formally under “Contraindications” — the practical effect, avoid in pregnancy, is unchanged.

For context on the broader “support compound” landscape people encounter alongside it:

Other AIs (letrozole, exemestane, testolactone) and SERMs / anti-estrogens (tamoxifen, clomifene, raloxifene, toremifene) are likewise prescription, non-controlled.
Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids and therefore Schedule III controlled substances under the Anabolic Steroid Control Act.
DNP (2,4-dinitrophenol) is not approved for human consumption; the FDA has warned against it for decades and it has a long history of fatal poisonings. It is not a medicine (see Safety).
Insulin and liothyronine (T3) are prescription drugs.

Anti-doping (WADA 2026 Prohibited List). Aromatase inhibitors (including anastrozole), anti-estrogens, and SERMs sit in Class S4 “Hormone and Metabolic Modulators,” prohibited at all times (in- and out-of-competition):

S4.1 Aromatase inhibitors: anastrozole, letrozole, exemestane, testolactone, formestane, aminoglutethimide, arimistane, and others. For 2026, WADA added 2-phenylbenzo[h]chromen-4-one (e.g., α-naphthoflavone / 7,8-benzoflavone) as an example AI.
S4.2 Anti-estrogenic substances / SERMs: anti-estrogens and SERMs (historically tamoxifen, clomifene, raloxifene, toremifene; the current WADA-listed example includes bazedoxifene).
S4.4 Insulins and other metabolic modulators: insulins are prohibited here, and for 2026 WADA added BAM15 (an AMPK activator) as an S4.4 metabolic modulator.

Separately, anabolic agents (S1) cover AAS such as mesterolone and fluoxymesterone (prohibited at all times), and DNP is captured under the metabolic-modulator / non-approved-substance provisions and is prohibited.

Safety

Anastrozole / AIs specifically:

Bone loss and fractures — the best-documented harm; AIs accelerate bone-mineral-density loss and raise fracture risk (clear in ATAC).
Aromatase-inhibitor arthralgia syndrome — common, sometimes severe joint pain and stiffness; a leading reason patients discontinue.
Vasomotor symptoms (hot flushes), fatigue, mood effects, and possible adverse lipid shifts (variable, generally modest for anastrozole).
In men, estrogen over-suppression → decreased libido and erectile function, increased body and visceral fat, and bone loss — because estrogen is essential to male bone and metabolic health (Finkelstein, NEJM 2013).
Avoid in pregnancy (fetal harm per label); no role in premenopausal women without ovarian suppression.

The genuinely dangerous companions people use alongside it — an honest comparison:

DNP (2,4-dinitrophenol) — the most lethal compound in this whole landscape, and it kills people. It is a mitochondrial uncoupler that causes uncontrolled metabolic heat production, producing fatal hyperthermia with NO antidote. Deaths have occurred even at “typical” misuse amounts; treatment is cooling and supportive care only. DNP has repeatedly been responsible for fatalities and is not safe in any amount for human consumption.
Insulin (non-diabetic / PED misuse) — can cause rapid, severe, potentially lethal hypoglycemia, seizures, irreversible brain injury, and death; the effect is unpredictable and unforgiving outside medical control.
SERMs (tamoxifen and others) — venous thromboembolism / clotting risk (PE, DVT, stroke) and endometrial effects.
T3 (liothyronine) — exogenous thyroid-hormone misuse causes tachyarrhythmias, cardiac strain, bone loss, and suppression of the endogenous thyroid axis; abrupt cessation can cause rebound hypothyroidism.
AAS (mesterolone, fluoxymesterone) — hepatotoxicity (especially oral 17α-alkylated agents like fluoxymesterone), adverse lipid and cardiovascular effects, and HPG-axis suppression.

None of the PED-support uses above are FDA-approved. Non-medical use means no medical monitoring, and the quality or contamination of non-pharmacy product is unknowable.

Bottom line

Anastrozole is a non-steroidal aromatase inhibitor — a prescription breast-cancer drug, not a SERM and not a peptide. In its approved population, postmenopausal women, the human evidence is strong: large randomized trials (ATAC, IBIS-II) document real benefit in HR+ breast cancer treatment and prevention, with bone loss and joint pain as the clearest harms. Its off-label use by men to suppress estrogen rests on real endocrine physiology but is unstudied for safety in healthy people, and well-controlled work (Finkelstein, NEJM 2013) shows that driving male estrogen too low backfires — more fat, less libido, and bone loss. It is a prescription drug (not a controlled substance) and is banned in sport at all times under WADA S4.1. Of the compounds people use alongside it, DNP is the standout danger: it has no antidote and has killed people.

Evidence grade: Strong human.

Anastrozole (Arimidex)